Enhancing cross-protection against influenza by heterologous sequential immunization with mRNA LNP and protein nanoparticle vaccines
Open Access
- 10 July 2024
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Abstract
Enhancing influenza vaccine cross-protection is imperative to alleviate the significant public health burden of influenza. Heterologous sequential immunization may synergize diverse vaccine formulations and routes to improve vaccine potency and breadth. Here we investigate the effects of immunization strategies on the generation of cross-protective immune responses in female Balb/c mice, utilizing mRNA lipid nanoparticle (LNP) and protein-based PHC nanoparticle vaccines targeting influenza hemagglutinin. Our findings emphasize the crucial role of priming vaccination in shaping Th bias and immunodominance hierarchies. mRNA LNP prime favors Th1-leaning responses, while PHC prime elicits Th2-skewing responses. We demonstrate that cellular and mucosal immune responses are pivotal correlates of cross-protection against influenza. Notably, intranasal PHC immunization outperforms its intramuscular counterpart in inducing mucosal immunity and conferring cross-protection. Sequential mRNA LNP prime and intranasal PHC boost demonstrate optimal cross-protection against antigenically drifted and shifted influenza strains. Our study offers valuable insights into tailoring immunization strategies to optimize influenza vaccine effectiveness.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI101047, R01AI143844)
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
This publication has 52 references indexed in Scilit:
- cGAMP-adjuvanted multivalent influenza mRNA vaccines induce broadly protective immunity through cutaneous vaccination in miceMolecular Therapy Nucleic Acids, 2022
- Monophosphoryl lipid A-adjuvanted nucleoprotein-neuraminidase nanoparticles improve immune protection against divergent influenza virusesNanomedicine: Nanotechnology, Biology and Medicine, 2022
- Engineered Nanoparticulate Vaccines to Combat Recurring and Pandemic Influenza ThreatsAdvanced NanoBiomed Research, 2021
- The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatoryiScience, 2021
- Tracking progress in universal influenza vaccine developmentCurrent Opinion in Virology, 2020
- Antibody-dependent cellular cytotoxicity and influenza virusCurrent Opinion in Virology, 2017
- Human influenza viruses and CD8+ T cell responsesCurrent Opinion in Virology, 2016
- Virus-specific T cells as correlate of (cross-)protective immunity against influenzaVaccine, 2015
- Heterologous prime–boost vaccinationCurrent Opinion in Immunology, 2009
- Immunoglobulin G subclass antibody responses of mice to influenza virus antigens given in different formsAntiviral Research, 1987